Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
TNYA Stock Forecast 2026-2027
$0.88
Current Price
$190.94M
Market Cap
Buy 8
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to TNYA Price Targets
+809.2%
To High Target of $8.00
+297.8%
To Median Target of $3.50
+127.3%
To Low Target of $2.00
TNYA Price Momentum
+11.4%
1 Week Change
+25.7%
1 Month Change
+27.5%
1 Year Change
+23.9%
Year-to-Date Change
-62.6%
From 52W High of $2.35
+65.4%
From 52W Low of $0.53
📊 TOP ANALYST CALLS
Did TNYA Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Tenaya is one of their latest high-conviction picks.
Latest TNYA Stock Price Targets & Analyst Predictions
Based on our analysis of 2 Wall Street analysts, TNYA has a bullish consensus with a median price target of $3.50 (ranging from $2.00 to $8.00). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $0.88, the median forecast implies a 297.8% upside. This outlook is supported by 8 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Geulah Livshits at Chardan Capital, projecting a 809.2% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TNYA Analyst Ratings
8
Buy
0
Hold
0
Sell
TNYA Price Target Range
Low
$2.00
Average
$3.50
High
$8.00
Current: $0.88
Latest TNYA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TNYA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 12, 2026 | Chardan Capital | Geulah Livshits | Buy | Maintains | $8.00 |
| Dec 18, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Dec 12, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Dec 12, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Nov 10, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Sep 2, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 27, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Aug 7, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| May 9, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Apr 25, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 31, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Mar 13, 2025 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Mar 12, 2025 | Morgan Stanley | Overweight | Maintains | $N/A | |
| Mar 12, 2025 | Chardan Capital | Buy | Maintains | $N/A | |
| Mar 11, 2025 | HC Wainwright & Co. | Buy | Maintains | $N/A | |
| Feb 3, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Jan 14, 2025 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Dec 18, 2024 | Chardan Capital | Buy | Maintains | $N/A | |
| Dec 18, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Nov 26, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A |
Tenaya Therapeutics, Inc. (TNYA) Competitors
The following stocks are similar to Tenaya based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
TNYA
Tenaya Therapeutics
mkt cap
170.76M
Tenaya Therapeutics, Inc. (TNYA) Financial Data
Tenaya Therapeutics, Inc. has a market capitalization of $190.94M with a P/E ratio of -1.5x. The company generates $225,000 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of -8,917.8% and return on equity of -73.6%.
Valuation Metrics
Market Cap
$190.94M
Enterprise Value
$120.17M
P/E Ratio
-1.5x
PEG Ratio
0.0x
Price/Sales
848.6x
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
-8,917.8%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+42.4%
Current Ratio
5.8x
Debt/Equity
9.5x
ROE
-73.6%
ROA
-38.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Tenaya Therapeutics, Inc. (TNYA) Business Model
About Tenaya Therapeutics, Inc.
What They Do
Develops gene therapy solutions for cardiovascular diseases.
Business Model
The company operates as a clinical-stage biotechnology firm, focusing on discovering and developing gene therapies to treat genetic heart conditions. It generates revenue primarily through partnerships and collaborations in research, alongside potential future product sales once therapies are commercialized.
Additional Information
Headquartered in South San Francisco, Tenaya Therapeutics leverages a proprietary adeno-associated virus platform for its therapies. Its lead program is in phase 2 clinical trials, with additional candidates targeting various heart conditions. The management team possesses significant expertise in gene therapy and biopharmaceutical development, aiming to meet the needs of patients with inherited heart diseases.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
70
CEO
Mr. Faraz Ali M.B.A.
Country
United States
IPO Year
2021
Website
www.tenayatherapeutics.comTenaya Therapeutics, Inc. (TNYA) Latest News & Analysis
Latest News
Quick Summary
A seasoned industry leader with 20 years of experience in finance, strategy, and operations has joined the team, potentially enhancing the company's leadership and expertise.
Why It Matters
A new leader with extensive finance and operational experience can drive strategic growth and enhance company performance, potentially increasing stock value and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Tenaya Therapeutics, Inc. (TNYA) presented at the Jefferies Global Healthcare Conference, showcasing its latest developments and strategic initiatives.
Why It Matters
Tenaya Therapeutics' presentation at a major healthcare conference could signal developments in its pipeline, impacting stock performance and investor sentiment in biotech.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
Tenaya Therapeutics (TNYA) presented interim data from the MyPEAK-1 trial regarding its TN-201 gene therapy for MYBPC3-associated hypertrophic cardiomyopathy (HCM).
Why It Matters
The interim data from Tenaya's MYPEAK-1 trial could indicate the potential effectiveness of TN-201, impacting stock performance and investor sentiment in biotech.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
All evaluable patients in a study on MYBPC3-associated HCM showed improvements. TN-201 received PRIME designation from EMA and entered FDA's Rare Disease process. Webcast at 8:00 a.m. ET.
Why It Matters
Positive clinical trial results for TN-201 indicate effective treatment for MYBPC3-associated HCM, enhancing investor confidence and potential market value for Tenaya Therapeutics.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Tenaya Therapeutics (NASDAQ: TNYA) will release interim data from its MyPEAK™-1 trial for TN-201 gene therapy in adults with HCM on June 3, 2026.
Why It Matters
New interim data from Tenaya Therapeutics' gene therapy trial could significantly impact stock prices and market sentiment, indicating progress in addressing heart disease.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Tenaya Therapeutics (NASDAQ: TNYA) will present at the Jefferies Global Healthcare Conference from June 2-4, 2026, with CEO Faraz Ali speaking on June 4 at 3:10 p.m. ET.
Why It Matters
Tenaya Therapeutics' presentation at a major healthcare conference could signal advancements in heart disease treatments, potentially influencing stock performance and investor sentiment.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About TNYA Stock
What is Tenaya Therapeutics, Inc.'s (TNYA) stock forecast for 2027?
Based on our analysis of 2 Wall Street analysts, Tenaya Therapeutics, Inc. (TNYA) has a median price target of $3.50. The highest price target is $8.00 and the lowest is $2.00.
Is TNYA stock a good investment in 2027?
According to current analyst ratings, TNYA has 8 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.88. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TNYA stock?
Wall Street analysts predict TNYA stock could reach $3.50 in the next 12 months. This represents a 297.8% increase from the current price of $0.88. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Tenaya Therapeutics, Inc.'s business model?
The company operates as a clinical-stage biotechnology firm, focusing on discovering and developing gene therapies to treat genetic heart conditions. It generates revenue primarily through partnerships and collaborations in research, alongside potential future product sales once therapies are commercialized.
What is the highest forecasted price for TNYA Tenaya Therapeutics, Inc.?
The highest price target for TNYA is $8.00 from Geulah Livshits at Chardan Capital, which represents a 809.2% increase from the current price of $0.88.
What is the lowest forecasted price for TNYA Tenaya Therapeutics, Inc.?
The lowest price target for TNYA is $2.00 from at , which represents a 127.3% increase from the current price of $0.88.
What is the overall TNYA consensus from analysts for Tenaya Therapeutics, Inc.?
The overall analyst consensus for TNYA is bullish. Out of 2 Wall Street analysts, 8 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $3.50.
How accurate are TNYA stock price projections?
Stock price projections, including those for Tenaya Therapeutics, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: July 9, 2026 1:01 PM UTC